Report
Alex Cogut ...
  • Maria Vara

ARC-EX launch delayed to H2 2024 but at a higher expected price with more lives covered

Following H1 2023 results, ONWARD's share price came under pressure due to a 6-months delay in the launch of ARC-EX in the US due to a component redesign. However, the company also announced a USD 30k/device launch price, which is 50% higher than our assumption and speaks to the unmet need in SCI d
Underlying
ONWARD MEDICAL NV

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Alex Cogut

Maria Vara

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch